The Effects of Buproprion on Residual and Cognitive Symptoms in SSRI-Treated Depression. - Article Depression/depressive Disorders
Clinical Trial: The Effects of Buproprion on Residual and Cognitive Symptoms in SSRI-Treated Depression.
This study is currently recruiting patients.
Verified by Mclean Hospital August 2005
Major Depressive Disorder
| Drug: buproprion ||Phase III |
MedlinePlus related topics: Depression; Mental Health
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Secondary Outcomes: self-report
Expected Total Enrollment: 30
Study start: August 2005; Expected completion: August 2006
Last follow-up: August 2006; Data entry closure: August 2006
As many as 65-75% of treated patients continue to experience residual symtoms of depression. Cognitive impairments feature frontal cognitive dysfunction. Many experts believe that executive functions are better predictors of functional level than psychiatric diagnosis.
Frontal cognitive impairment and changes in neuroimaging is seen in individuals depleted of tryptophan, a serotonin precursor. These cognitive changes do not improve following serotonin-specific reuptake inhibitor treatment and at least one study has found that executive dysfunction predicts non-response to fluoxetine. In many patients, remission of mood symptoms in depression requires medications to target non-serotonergic neurotransmitter systems. Brain areas mediating executive functions receive rich noradrenergic inputs, and norepinephrine is known to be intimately involved in many of the executive functions.
A better understanding of serotonergic and catecholaminergic interactions would enable evidence-based treatment of depression which maximizes executive cognitive functions. This study examines the hypothesis that invididuals treated with buproprion will have higher scores on tests of executive functions and lower scores on depression indices.
Inclusion Criteria: depression SSRI-treated
Location and Contact Information
McLean Hospital, Belmont, Massachusetts, 02478, United States; Recruiting
Beth L Murphy, MD, PhD, Principal Investigator
J. Alexander Bodkin, MD, Sub-Investigator
Beth L Murphy, MD, PhD, Principal Investigator, Mclean Hospital
Last Updated: August 1, 2005
Record first received: August 1, 2005
ClinicalTrials.gov Identifier: NCT00125957
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-08-02
- "Care Managers" Help Depressed Elderly Reduce Suicidal Thoughts (National Institutes of Health)
- 5-HTP:Nature''s Serotonin Solution? (HealthWorld)